TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis
NASDAQ:TVTX - Nasdaq - US89422G1076 - Common Stock - Currency: USD
Overall TVTX gets a fundamental rating of 2 out of 10. We evaluated TVTX against 572 industry peers in the Biotechnology industry. TVTX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TVTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TVTX has reported negative net income.
TVTX had a negative operating cash flow in the past year.
TVTX had negative earnings in each of the past 5 years.
TVTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TVTX has a worse Return On Assets (-69.68%) than 66.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.68% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-26.24%
ROA(5y)-26.16%
ROE(3y)-254.76%
ROE(5y)-182.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TVTX has a Gross Margin of 95.21%. This is amongst the best in the industry. TVTX outperforms 95.93% of its industry peers.
TVTX's Gross Margin has been stable in the last couple of years.
TVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.68%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TVTX has more shares outstanding
The number of shares outstanding for TVTX has been increased compared to 5 years ago.
The debt/assets ratio for TVTX has been reduced compared to a year ago.
2.2 Solvency
TVTX has an Altman-Z score of -3.02. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
TVTX's Altman-Z score of -3.02 is in line compared to the rest of the industry. TVTX outperforms 46.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.02 |
ROIC/WACCN/A
WACC10.08%
2.3 Liquidity
A Current Ratio of 1.71 indicates that TVTX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.71, TVTX is not doing good in the industry: 80.35% of the companies in the same industry are doing better.
A Quick Ratio of 1.68 indicates that TVTX should not have too much problems paying its short term obligations.
The Quick ratio of TVTX (1.68) is worse than 79.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.68 |
3. Growth
3.1 Past
TVTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.35%.
TVTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.37%.
Measured over the past years, TVTX shows a decrease in Revenue. The Revenue has been decreasing by -2.42% on average per year.
EPS 1Y (TTM)4.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.17%
Revenue 1Y (TTM)30.37%
Revenue growth 3Y-9.86%
Revenue growth 5Y-2.42%
Sales Q2Q%69.56%
3.2 Future
Based on estimates for the next years, TVTX will show a very strong growth in Earnings Per Share. The EPS will grow by 23.88% on average per year.
TVTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.83% yearly.
EPS Next Y16.7%
EPS Next 2Y31.25%
EPS Next 3Y28.99%
EPS Next 5Y23.88%
Revenue Next Year18.73%
Revenue Next 2Y38.58%
Revenue Next 3Y40.97%
Revenue Next 5Y33.83%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
Also next year TVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TVTX's earnings are expected to grow with 28.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.25%
EPS Next 3Y28.99%
5. Dividend
5.1 Amount
No dividends for TVTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRAVERE THERAPEUTICS INC
NASDAQ:TVTX (1/28/2025, 8:09:05 PM)
After market: 21.26 +0.16 (+0.76%)21.1
+0.97 (+4.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners117.03%
Inst Owner Change0.35%
Ins Owners0.83%
Ins Owner Change0.71%
Market Cap1.81B
Analysts84.76
Price Target28.15 (33.41%)
Short Float %10.31%
Short Ratio6.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.31%
Min EPS beat(2)-3.62%
Max EPS beat(2)-1%
EPS beat(4)1
Avg EPS beat(4)-14.53%
Min EPS beat(4)-74.13%
Max EPS beat(4)20.64%
EPS beat(8)3
Avg EPS beat(8)-94.9%
EPS beat(12)3
Avg EPS beat(12)-71.59%
EPS beat(16)5
Avg EPS beat(16)-62.4%
Revenue beat(2)2
Avg Revenue beat(2)3.86%
Min Revenue beat(2)1.97%
Max Revenue beat(2)5.75%
Revenue beat(4)3
Avg Revenue beat(4)2.36%
Min Revenue beat(4)-5.33%
Max Revenue beat(4)7.06%
Revenue beat(8)6
Avg Revenue beat(8)-4.65%
Revenue beat(12)6
Avg Revenue beat(12)-15.81%
Revenue beat(16)8
Avg Revenue beat(16)-11.5%
PT rev (1m)2.46%
PT rev (3m)60.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)14.49%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)2.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.89 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.4
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-4.31
FCFYN/A
OCF(TTM)-3.18
OCFYN/A
SpS2.37
BVpS-0.36
TBVpS-1.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.68% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.21% | ||
| FCFM | N/A |
ROA(3y)-26.24%
ROA(5y)-26.16%
ROE(3y)-254.76%
ROE(5y)-182.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.68%
GM growth 5Y-0.96%
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 237.29% | ||
| Cap/Sales | 47.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z | -3.02 |
F-Score3
WACC10.08%
ROIC/WACCN/A
Cap/Depr(3y)95.58%
Cap/Depr(5y)92.6%
Cap/Sales(3y)17.73%
Cap/Sales(5y)14.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.17%
EPS Next Y16.7%
EPS Next 2Y31.25%
EPS Next 3Y28.99%
EPS Next 5Y23.88%
Revenue 1Y (TTM)30.37%
Revenue growth 3Y-9.86%
Revenue growth 5Y-2.42%
Sales Q2Q%69.56%
Revenue Next Year18.73%
Revenue Next 2Y38.58%
Revenue Next 3Y40.97%
Revenue Next 5Y33.83%
EBIT growth 1Y22.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.08%
EBIT Next 3Y24.74%
EBIT Next 5Y21.47%
FCF growth 1Y-96.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.72%
OCF growth 3YN/A
OCF growth 5YN/A